Categories Earnings, Health Care
Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot
— Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth quarter of 2019, compared to a loss of $6.1 million or $0.85 per share last year. Analysts had forecast a loss of $0.61 per share.
— Being a development-stage biopharmaceutical company, Catabasis did nor record revenues in the December-quarter
— Research & Development expenses increased 16% year-over-year to $4.3 million during the three-month period
— At $2.5 million, selling, general and administrative expenses were up 4% from the year-ago period
— As of December 2019, cash, cash equivalents and short-term investments were $36.2 million, compared to $40.6 million as of September 2019
— Expects to fund operations through a potential NDA filing and into the third quarter of 2021, using available cash
— Expects to publish top results from the phase-3 PolarisDMD trial of edasalonexent, in Duchenne muscular dystrophy, in the fourth quarter of 2020
Most Popular
Electronic Arts (EA) Q4 earnings drop and miss estimates; revenue down 3%
Video game company Electronic Arts, Inc. (NASDAQ: EA) reported lower earnings and revenues for the fourth quarter of 2021. Earnings also missed analysts' forecast. During the March quarter, net bookings
What lies in store for Tyson Foods (TSN) this year?
Shares of Tyson Foods Inc. (NYSE: TSN) were in green territory during afternoon hours on Tuesday. The stock has gained 32% over the past 12 months and 23% since the
Virgin Galactic (SPCE) fails to impress market amid looming uncertainty
Space tourism company Virgin Galactic Holdings, Inc. (NYSE: SPCE) ended the first quarter of 2021 without generating revenue and continued the losing streak even as uncertainty over its test flight
